The market managed to stop Wednesday’s strong selloff with a respectable bounceback on Thursday, but, the issue still hangs in the balance. The volume behind the gain was modest, and the indices are still within easy reach of a technical breakdown.
The bulk of Thursday’s limited number of fireworks were provided courtesy of Amazon (NASDAQ:AMZN). The e-commerce giant said it was acquiring online pharmacy PillPack, sending traditional pharmacy stocks like CVS Health (NYSE:CVS), Rite Aid (NYSE:RAD) and Walgreens Boots Alliance (NASDAQ:WBA) careening.
None of those names are well-suited for trading now though … too much volatility makes it impossible to get a read on what’s to come. Rather, the best bets from here are Sherwin-Williams (NYSE:SHW), Regeneron (NASDAQ:REGN) and Allstate (NYSE:ALL), each of which are relatively immune to the market’s normal recycling of hysteria.
Sherwin-Williams (SHW)

There’s nothing sexy about Sherwin-Williams, even when factoring in that it’s more than just paint. It’s also an industrial coating specialist, which is an industry that’s well-positioned to capitalize on broad economic growth.
Yet, SHW stock is compelling here, even if only for technical reasons.

Click to Enlarge
• Also note that we’re still seeing more bullish volume than bearish volume, even if that trend is erratic.
• While “boring,” this stock has an impressive long-term track record. SHW shares are up more than 200% over the course of the past six years, and the momentum still seems as intact as it ever has.
Regeneron (REGN)

For a multitude of reasons, the summertime is a bullish time of year for biotech stocks even if it’s a disappointing time of year the overall market. To that end, Regeneron Pharmaceuticals is as much of sector-timing play as it is a stock-specific trade.
Even on a stock-specific basis though, this chart looks like it’s in breakout mode.

Click to Enlarge
• The daily chart has easily pushed past its 50-day moving average line, and not looked back.
• There’s also plenty of volume behind the past several days’ worth of gains. And, that bullish volume appears to be growing.
Allstate Corp (ALL)

Not every worthy trading prospect is a bullish one right now though. Like many other insurers of late, Allstate is fighting a losing battle, and just suffered tough blow in a vulnerable state. Insurers, as a group, are also falling out of favor against the back drop of rising rates and the foreseeable future of interest rates.

Click to Enlarge
• Thanks to Wednesday’s plunge, two key support levels — at $91.61 and $91.05 — have been broken. Thursday’s gain only partially unwound that blow. The shape of the monthly chart shows a gradual, ongoing downside acceleration. One more bad day could push Allstate over the edge.
• The daily chart also shows that the volume behind the recent “up” days has been lower than the “down” day volume.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley.
Legendary Investor Louis Navellier’s Trading Breakthrough
Discovered almost by accident, Louis Navellier’s incredible trading breakthrough has delivered 148 double- and triple-digit winners over the last 5 years — including a stunning 487% win in just 10 months.
Learn to use this formula and you can start turning every $10,000 invested into as much as $58,700.
Click here to review Louis’ urgent presentation.